Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'

May 14, 2026 8:35 AM

Jefferies analyst Andrew Tsai reiterated a Buy rating and $210.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "Topline details ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'

Categories